NEW YORK (GenomeWeb News) – Strand Life Sciences will work with two institutes on a study in India that aims to identify and validate biomarkers for breast cancer, the Bangalore-based firm said Wednesday.
Strand will partner with the Kidwai Memorial Institute of Oncology and the Indian Institute of Science (IISc) to study more than 300 adult Indian women suffering from breast cancer in an effort to generate molecular signatures that could be used to predict response to various therapies and treatments, metastasis, relapse, and disease-free survival rates.
Strand plans to compare publicly available data from African and Caucasian cohorts with data from this study. It will use the results to develop and identify biological markers that can characterize subtypes and develop diagnostic kits that could be used in making predictions about therapeutic actions.
The company said that breast cancer has overtaken ovarian cancer as the second leading cause of death among women in India's urban centers. Strand also said that recent data suggests that "a startling number of pre-menopausal, young Indian women" are being stricken with the disease.
"It is for the first time in India that such a detailed study of molecular signatures is being undertaken to understand the occurrence and prevalence of breast cancer in the country," Strand Chairman and CEO Vijay Chandru said in a statement. "The objective of this study is to enable groundbreaking research that holds promise to make new, potentially lifesaving discoveries for the Indian population, and we are honored to play a part in unlocking that discovery."
The tumor samples will be provided by the Kidwai Institute and they will be profiled by IISc. Strand will provide in silico analysis of microarray data.